These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 20356555

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A, Avalos C, Orellana G, Cifuentes C, Rivas J, Calderón F.
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [Abstract] [Full Text] [Related]

  • 4. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P, Behounek J, Skoták M, Nevsímal L.
    Acta Chir Orthop Traumatol Cech; 2004 Jun; 71(4):237-44. PubMed ID: 15456102
    [Abstract] [Full Text] [Related]

  • 5. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
    Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR.
    Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
    [Abstract] [Full Text] [Related]

  • 6. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD, Müller U, Lanzmich R, Groeger C, Floege J.
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [Abstract] [Full Text] [Related]

  • 7. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY, Hawthorne WJ, Coombs R, Fletcher JP.
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [Abstract] [Full Text] [Related]

  • 8. The safety of heparins in end-stage renal disease.
    Sonawane S, Kasbekar N, Berns JS.
    Semin Dial; 2006 Jun; 19(4):305-10. PubMed ID: 16893408
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of optimal dosage of heparin in hemodialysis patients by thromboelastograph].
    Yang ST, Wu H, Gao XY, Hu J, Xiao YF.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Aug 18; 45(4):625-9. PubMed ID: 23939176
    [Abstract] [Full Text] [Related]

  • 10. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
    Minamiguchi K, Kitazato KT, Sasaki E, Nagase H, Kitazato K.
    Thromb Haemost; 1997 Jun 18; 77(6):1148-53. PubMed ID: 9241748
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin.
    Camici M, Giordani R, Morelli E, Meriggioli M, Balestri PL, Barsotti G, Sagripanti A.
    Minerva Med; 1998 Jun 18; 89(11-12):405-9. PubMed ID: 10212664
    [Abstract] [Full Text] [Related]

  • 12. [Epidemiology of anticoagulation for hemodialysis patients: survey of 842 cases in seven hemodialysis centers].
    Sun XF, Xiao Q, Wang Y, Hao LR, Lin HL, Zhang ZM, Li JJ, Chen XM.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 10; 89(9):577-81. PubMed ID: 19595154
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.
    Elisaf MS, Bairaktari H, Germanos N, Pappas M, Koulouridis E, Papagalanis N, Siamopoulos KC.
    Int Angiol; 1996 Sep 10; 15(3):252-6. PubMed ID: 8971586
    [Abstract] [Full Text] [Related]

  • 14. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
    Liu ZQ, Wang L.
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct 10; 22(10):942-3. PubMed ID: 12377628
    [Abstract] [Full Text] [Related]

  • 15. Effects of heparin and dalteparin on oxidative stress during hemodialysis in patients with end-stage renal disease.
    Nassiri AA, Hakemi MS, Soulati M, Marashian M, Rahbar K, Azizi F.
    Iran J Kidney Dis; 2009 Jul 10; 3(3):162-7. PubMed ID: 19617666
    [Abstract] [Full Text] [Related]

  • 16. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
    Suzuki T, Ota K, Naganuma S, Koshikawa S, Hirasawa Y, Nakagawa S, Otsubo O, Akizawa T.
    Semin Thromb Hemost; 1990 Oct 10; 16 Suppl():46-54. PubMed ID: 1962904
    [Abstract] [Full Text] [Related]

  • 17. Effects of standard unfractionated and low-molecular-weight heparins on platelets of patients undergoing total hip replacement surgery.
    Aulmann M, Kwasniki S, Böttiger BW, Meeder PJ.
    Beitr Infusionsther Transfusionsmed; 1997 Oct 10; 34():242-7. PubMed ID: 9356680
    [Abstract] [Full Text] [Related]

  • 18. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
    Lord H, Jean N, Dumont M, Kassis J, Leblanc M.
    Am J Nephrol; 2002 Oct 10; 22(1):58-66. PubMed ID: 11919404
    [Abstract] [Full Text] [Related]

  • 19. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
    Poyrazoglu OK, Dogukan A, Yalniz M, Seckin D, Gunal AL.
    Ren Fail; 2006 Oct 10; 28(8):723-7. PubMed ID: 17162433
    [Abstract] [Full Text] [Related]

  • 20. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.
    Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P.
    Nephrol Dial Transplant; 2008 Jun 10; 23(6):2003-9. PubMed ID: 18156457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.